Epitopea

Epitopea is a transatlantic cancer immunotherapy company founded in 2021, with headquarters in Cambridge, UK, and Montreal, Canada. The company focuses on developing off-the-shelf RNA-based immunotherapies that target a novel class of tumor-specific antigens known as Cryptigens™. These antigens are uniquely expressed across patients with the same tumor type, making them promising targets for treatment. The company's primary therapeutic approach is through its CryptiVax™ platform, which allows for the development of various treatment modalities, including therapeutic vaccines and TCR- or antibody-based bi-specifics. Epitopea is advancing its RNA-based immunotherapies into clinical trials and has established a dedicated clinical team to enhance its research capabilities. The company has secured over US$13 million in funding from a range of life sciences investors, supporting its mission to address difficult-to-cure cancers.